Opioid system and related ligands: from the past to future perspectives.
Biased agonists
Bifunctional agonists
Chronic pain
OIH
OUD (opioid use disorder)
Opioids
Tolerance
Journal
Journal of anesthesia, analgesia and critical care
ISSN: 2731-3786
Titre abrégé: J Anesth Analg Crit Care
Pays: England
ID NLM: 9918591885906676
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
05
07
2024
accepted:
06
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Chronic pain is a pathological condition affecting about 30% of population. It represents a relevant social-health issue worldwide, and it is considered a significant source of human suffering and disability, strongly affecting patients' quality of life. Despite several pharmacological strategies to guarantee an adequate pain management have been proposed over the years, opioids still represent one of the primary choices for treating moderate-to-severe pain in both cancer and non-cancer patients. However, chronic use of opioids often leads to numerous side effects, including respiratory depression, constipation, analgesic tolerance, and opioid-induced hyperalgesia (OIH), which can strongly limit their use. Given the fundamental role of opioid system in pain relief, this review provides a general overview about the main actors (endogenous opioid peptides and receptors) involved in its modulation. Furthermore, this review explores the action and the limitations of conventional clinically used opioids and describes the efficacy and safety profile of some promising analgesic compounds. A deeper understanding of the molecular mechanisms behind both analgesic effects and adverse events could advance knowledge in this field, thus improving chronic pain treatment.
Identifiants
pubmed: 39390585
doi: 10.1186/s44158-024-00201-2
pii: 10.1186/s44158-024-00201-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
70Informations de copyright
© 2024. The Author(s).
Références
Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand’homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ (2019) Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 160(1):19–27. https://doi.org/10.1097/j.pain.0000000000001384
doi: 10.1097/j.pain.0000000000001384
Coluzzi F, Rullo L, Scerpa MS, Losapio LM, Rocco M, Billeci D, Candeletti S, Romualdi P (2022) Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs 36(6):617–632. https://doi.org/10.1007/s40263-022-00924-2
doi: 10.1007/s40263-022-00924-2
Flores-García M, Rizzo A, Garçon-Poca MZ, Fernández-Dueñas V, Bonaventura J (2023) Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub. Front Pharmacol 14:1278023. https://doi.org/10.3389/fphar.2023.1278023
doi: 10.3389/fphar.2023.1278023
Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58–68. https://doi.org/10.1016/S1470-2045(12)70040-2
Ambrosio F, Finco G, Mattia C, Mediati R, Paoletti F, Coluzzi F, Piacevoli Q, Savoia G, Amantea B, Aurilio C, Bonezzi C, Camaioni D, Chiefari M, Costantini A, Evangelista M, Ischia S, Mondello E, Polati E, Raffaeli W, Sabato AF, Varrassi G, Visentin M, Tufano R (2006) SIAARTI Chronic Non-Cancer Pain Study Group SIAARTI recommendations for chronic noncancer pain. Minerva Anestesiol 72(11):859–880
Coluzzi F, Alvaro D, Caraceni AT, Gianni W, Marinangeli F, Massazza G, Pinto C, Varrassi G, Lugoboni F (2021) Common clinical practice for opioid-induced constipation: a physician survey. J Pain Res 14:2255–2264. https://doi.org/10.2147/JPR.S318564
doi: 10.2147/JPR.S318564
Mercadante S, Arcuri E, Santoni A (2019) Opioid-induced tolerance and hyperalgesia. CNS Drugs 33(10):943–955. https://doi.org/10.1007/s40263-019-00660-0
doi: 10.1007/s40263-019-00660-0
Cahill CM, Walwyn W, Taylor AMW, Pradhan AAA, Evans CJ (2016) Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol Sci 37(11):963–976. https://doi.org/10.1016/j.tips.2016.08.002
doi: 10.1016/j.tips.2016.08.002
Pergolizzi JV, Raffa RB, Rosenblatt MH (2020) Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther 45(5):892–903. https://doi.org/10.1111/jcpt.13114
doi: 10.1111/jcpt.13114
Volkow ND, Blanco C (2021) The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry 26(1):218–233. https://doi.org/10.1038/s41380-020-0661-4
doi: 10.1038/s41380-020-0661-4
Lambert DG, Bird MF, Rowbotham DJ (2015) Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth 114(3):364–366. https://doi.org/10.1093/bja/aeu332
doi: 10.1093/bja/aeu332
Raffa RB, Burdge G, Gambrah J, Kinecki HE, Lin F, Lu B, Nguyen JT, Phan V, Ruan A, Sesay MA, Watkins TN (2017) Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. J Clin Pharm Ther 42(1):8–17. https://doi.org/10.1111/jcpt.12461
doi: 10.1111/jcpt.12461
Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC (2019) BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br J Anaesth 122(6):e146–e156. https://doi.org/10.1016/j.bja.2018.10.065
doi: 10.1016/j.bja.2018.10.065
Kiguchi N, Ding H, Ko MC (2022) Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J Neurosci Res 100(1):191–202. https://doi.org/10.1002/jnr.24624
doi: 10.1002/jnr.24624
Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336(2):296–302. https://doi.org/10.1124/jpet.110.173948
doi: 10.1124/jpet.110.173948
Bohn LM, Lefkowitz RJ, Caron MG (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22(23):10494–10500. https://doi.org/10.1523/JNEUROSCI.22-23-10494.2002
doi: 10.1523/JNEUROSCI.22-23-10494.2002
Romualdi P, Candeletti S (2018) The opioid system. in: Clementi F, Fumagalli G, editors. General and molecular pharmacology. 5th ed. EDRA; p. 557–568
Koob GF, Arends MA, Le Moal M (2014) Drugs, addiction, and the brain. Academic Press. https://doi.org/10.1016/B978-0-12-386937-1.01001-1
Corder G, Castro DC, Bruchas MR, Scherrer G (2018) Endogenous and exogenous opioids in pain. Annu Rev Neurosci 41:453–473. https://doi.org/10.1146/annurev-neuro-080317-061522
doi: 10.1146/annurev-neuro-080317-061522
Gach-Janczak K, Biernat M, Kuczer M, Adamska-Bartłomiejczyk A, Kluczyk A (2024) Analgesic peptides: from natural diversity to rational design. Molecules 29(7):1544. https://doi.org/10.3390/molecules29071544
doi: 10.3390/molecules29071544
Mika J, Obara I, Przewlocka B (2011) The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction. Neuropeptides 45(4):247–261. https://doi.org/10.1016/j.npep.2011.03.002
doi: 10.1016/j.npep.2011.03.002
Fricker LD, Margolis EB, Gomes I, Devi LA (2020) Five decades of research on opioid peptides: current knowledge and unanswered questions. Mol Pharmacol 98(2):96–108. https://doi.org/10.1124/mol.120.119388
doi: 10.1124/mol.120.119388
Margolis EB, Moulton MG, Lambeth PS, O’Meara MJ (2023) The life and times of endogenous opioid peptides: updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. Neuropharmacology 225:109376. https://doi.org/10.1016/j.neuropharm.2022.109376
doi: 10.1016/j.neuropharm.2022.109376
Yoshikawa K, Williams C, Sabol SL (1984) Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system. J Biol Chem. 259(22):14301–14308
doi: 10.1016/S0021-9258(18)89893-3
Kuspiel S, Wiemuth D, Gründer S (2021) The neuropeptide nocistatin is not a direct agonist of acid-sensing ion channel 1a (ASIC1a). Biomolecules 11(4):571. https://doi.org/10.3390/biom11040571
doi: 10.3390/biom11040571
Benarroch EE (2012) Endogenous opioid systems: current concepts and clinical correlations. Neurology 79(8):807–814. https://doi.org/10.1212/WNL.0b013e3182662098
doi: 10.1212/WNL.0b013e3182662098
Holden JE, Jeong Y, Forrest JM (2005) The endogenous opioid system and clinical pain management. AACN Clin Issues 16(3):291–301. https://doi.org/10.1097/00044067-200507000-00003
doi: 10.1097/00044067-200507000-00003
Caputi FF, Rullo L, Stamatakos S, Candeletti S, Romualdi P (2019) Modulation of the negative affective dimension of pain: focus on selected neuropeptidergic system contributions. Int J Mol Sci 20(16):4010. https://doi.org/10.3390/ijms20164010
doi: 10.3390/ijms20164010
Lamberts JT, Traynor JR (2013) Opioid receptor interacting proteins and the control of opioid signaling. Curr Pharm Des 19(42):7333–7347. https://doi.org/10.2174/138161281942140105160625
doi: 10.2174/138161281942140105160625
Taussig R, Iñiguez-Lluhi JA, Gilman AG (1993) Inhibition of adenylyl cyclase by Gi alpha. Science 261(5118):218–221. https://doi.org/10.1126/science.8327893
doi: 10.1126/science.8327893
Ippolito DL, Temkin PA, Rogalski SL, Chavkin C (2002) N-terminal tyrosine residues within the potassium channel Kir3 modulate GTPase activity of Galphai. J Biol Chem 277(36):32692–32696. https://doi.org/10.1074/jbc.M204407200
doi: 10.1074/jbc.M204407200
Torrecilla M, Quillinan N, Williams JT, Wickman K (2008) Pre- and postsynaptic regulation of locus coeruleus neurons after chronic morphine treatment: a study of GIRK-knockout mice. Eur J Neurosci 28(3):618–624. https://doi.org/10.1111/j.1460-9568.2008.06348.x
doi: 10.1111/j.1460-9568.2008.06348.x
Bourinet E, Soong TW, Stea A, Snutch TP (1996) Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A 93(4):1486–1491. https://doi.org/10.1073/pnas.93.4.1486
doi: 10.1073/pnas.93.4.1486
Acevedo-Canabal A, Pantouli F, Ravichandran A, Rullo L, Bohn L (2021) Pharmacological diversity in opioid analgesics: lessons from clinically useful drugs. In: Reference Module in Biomedical Sciences; https://doi.org/10.1016/B978-0-12-820472-6.00188-2
Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5(1):60–68. https://doi.org/10.1016/j.coph.2004.08.012
doi: 10.1016/j.coph.2004.08.012
Gledhill LJ, Babey AM (2021) Synthesis of the mechanisms of opioid tolerance: do we still say no? Cell Mol Neurobiol 41(5):927–948. https://doi.org/10.1007/s10571-021-01065-8
doi: 10.1007/s10571-021-01065-8
Fan P, Jiang Z, Diamond I, Yao L (2009) Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons. Mol Pharmacol 76(3):526–533. https://doi.org/10.1124/mol.109.057802
doi: 10.1124/mol.109.057802
Chartoff EH, Papadopoulou M, Konradi C, Carlezon WA (2003) Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum. J Neurochem 87(1):107–118. https://doi.org/10.1046/j.1471-4159.2003.01992.x
doi: 10.1046/j.1471-4159.2003.01992.x
Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154(2):384–396. https://doi.org/10.1038/bjp.2008.100
doi: 10.1038/bjp.2008.100
Taylor JL, Samet JH(2022) Opioid use disorder. Ann Intern Med 175(1):ITC1-ITC16. https://doi.org/10.7326/AITC202201180
Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8):760–773. https://doi.org/10.1016/S2215-0366(16)00104-8
doi: 10.1016/S2215-0366(16)00104-8
Koob GF (2021) Drug addiction: hyperkatifeia/negative reinforcement as a framework for medications development. Pharmacol Rev 73(1):163–201. https://doi.org/10.1124/pharmrev.120.000083
doi: 10.1124/pharmrev.120.000083
Kosten TR, George TP (2002) The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1(1):13–20. https://doi.org/10.1151/spp021113
doi: 10.1151/spp021113
Karkhanis A, Holleran KM, Jones SR (2017) Dynorphin/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction. Int Rev Neurobiol 136:53–88. https://doi.org/10.1016/bs.irn.2017.08.001
doi: 10.1016/bs.irn.2017.08.001
Nielsen DA, Utrankar A, Reyes JA, Simons DD, Kosten TR (2012) Epigenetics of drug abuse: predisposition or response. Pharmacogenomics 13(10):1149–1160. https://doi.org/10.2217/pgs.12.94
doi: 10.2217/pgs.12.94
Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8(11):1450–1457. https://doi.org/10.1038/nn1583
doi: 10.1038/nn1583
Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T (2010) Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci 31(7):299–305. https://doi.org/10.1016/j.tips.2010.04.003
doi: 10.1016/j.tips.2010.04.003
Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM (2015) Pain and poppies: the good, the bad, and the ugly of opioid analgesics. J Neurosci 35(41):13879–13888. https://doi.org/10.1523/JNEUROSCI.2711-15.2015
doi: 10.1523/JNEUROSCI.2711-15.2015
Ibrahim KM, Massaly N, Yoon HJ, Sandoval R, Widman AJ, Heuermann RJ, Williams S, Post W, Pathiranage S, Lintz T, Zec A, Park A, Yu W, Kash TL, Gereau RW 4th (2024) Morón JADorsal hippocampus to nucleus accumbens projections drive reinforcement via activation of accumbal dynorphin neurons. Nat Commun 15:750. https://doi.org/10.1038/s41467-024-44836-9
doi: 10.1038/s41467-024-44836-9
Wicks C, Hudlicky T, Rinner U (2021) Morphine alkaloids: history, biology, and synthesis. Alkaloids Chem Biol 86:145–342. https://doi.org/10.1016/bs.alkal.2021.04.001
doi: 10.1016/bs.alkal.2021.04.001
Murphy PB, Bechmann S, Barrett MJ (2024) Morphine. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK526115/
Listos J, Łupina M, Talarek S, Mazur A, Orzelska-Górka J, Kotlińska J (2019) The mechanisms involved in morphine addiction: an overview. Int J Mol Sci 20(17):4302. https://doi.org/10.3390/ijms20174302
doi: 10.3390/ijms20174302
Stein C (2013) Targeting pain and inflammation by peripherally acting opioids. Front Pharmacol 4:123. https://doi.org/10.3389/fphar.2013.00123
doi: 10.3389/fphar.2013.00123
Badshah I, Anwar M, Murtaza B, Khan MI. Molecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives. Mol Cell Biochem. Published online July 20, 2023. https://doi.org/10.1007/s11010-023-04810-3
Oxycodone KE (2005) J Pain Symptom Manage 29(5 Suppl):S47-56. https://doi.org/10.1016/j.jpainsymman.2005.01.010
doi: 10.1016/j.jpainsymman.2005.01.010
Olkkola KT, Kontinen VK, Saari TI, Kalso EA (2013) Does the pharmacology of oxycodone justify its increasing use as an analgesic? Trends Pharmacol Sci 34(4):206–214. https://doi.org/10.1016/j.tips.2013.02.001
doi: 10.1016/j.tips.2013.02.001
Burness CB, Keating GM (2014) Oxycodone/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 74(3):353–375. https://doi.org/10.1007/s40265-014-0177-9
doi: 10.1007/s40265-014-0177-9
Coluzzi F, Caputi FF, Billeci D, Pastore AL, Candeletti S, Rocco M, Romualdi P (2020) Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther Clin Risk Manag 16:821–837. https://doi.org/10.2147/TCRM.S262843
doi: 10.2147/TCRM.S262843
Jayawardana S, Forman R, Johnston-Webber C, Campbell A, Berterame S, de Joncheere C, Aitken M (2021) Mossialos EGlobal consumption of prescription opioid analgesics between 2009–2019: a country-level observational study. EClinicalMedicine 42:101198. https://doi.org/10.1016/j.eclinm.2021.101198
doi: 10.1016/j.eclinm.2021.101198
Peng PW, Sandler AN (1999) A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90(2):576–599. https://doi.org/10.1097/00000542-199902000-00034
doi: 10.1097/00000542-199902000-00034
Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB (1993) The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci 52(4):389–396. https://doi.org/10.1016/0024-3205(93)90152-s
doi: 10.1016/0024-3205(93)90152-s
Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK (2022) Synthetic opioids: a review and clinical update. Ther Adv Psychopharmacol 12:20451253221139616. https://doi.org/10.1177/20451253221139616
doi: 10.1177/20451253221139616
Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L (2019) The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry 9(1):282. https://doi.org/10.1038/s41398-019-0625-0
doi: 10.1038/s41398-019-0625-0
Suzuki J, El-Haddad S (2017) A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend 171:107–116. https://doi.org/10.1016/j.drugalcdep.2016.11.033
doi: 10.1016/j.drugalcdep.2016.11.033
Wang W, He Q, Wang M, Kang Y, Ji P, Zhu S, Zhang R, Zou K (2022) Sun X Associations of fentanyl, sufentanil, and remifentanil with length of stay and mortality among mechanically ventilated patients: a registry-based cohort study. Front Pharmacol 13:858531. https://doi.org/10.3389/fphar.2022.858531
doi: 10.3389/fphar.2022.858531
Leen JLS, Juurlink DN (2019) Carfentanil: a narrative review of its pharmacology and public health concerns. Can J Anaesth 66(4):414–421. https://doi.org/10.1007/s12630-019-01294-y
doi: 10.1007/s12630-019-01294-y
Blum J, Gerber H, Gerhard U, Schmid O, Petitjean S, Riecher-Rössler A, Wiesbeck GA, Borgwardt SJ, Walter M (2013) Acute effects of heroin on emotions in heroin-dependent patients. Am J Addict 22(6):598–604. https://doi.org/10.1111/j.1521-0391.2013.12025.x
doi: 10.1111/j.1521-0391.2013.12025.x
Goldstein A (1991) Heroin addiction: neurobiology, pharmacology, and policy. J Psychoactive Drugs 23(2):123–133. https://doi.org/10.1080/02791072.1991.10472231
doi: 10.1080/02791072.1991.10472231
Spencer MR, Miniño AM, Warner M (2022) Drug overdose deaths in the United States, 2001–2021. NCHS Data Brief 457:1–8
Srivastava A, Kahan M, Nader M (2017) Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician 63(3):200–205
Kumar R, Viswanath O, Saadabadi A (2024) Buprenorphine. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK459126/
Gudin J, Fudin J (2020) A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 9(1):41–54. https://doi.org/10.1007/s40122-019-00143-6
doi: 10.1007/s40122-019-00143-6
Gerhold KJ, Drdla-Schutting R, Honsek SD, Forsthuber L, Sandkühler J (2015) Pronociceptive and antinociceptive effects of buprenorphine in the spinal cord dorsal horn cover a dose range of four orders of magnitude. J Neurosci 35(26):9580–94. https://doi.org/10.1523/JNEUROSCI.0731-14.2015
Ding Z, Raffa RB (2009) Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol 157(5):831–843. https://doi.org/10.1111/j.1476-5381.2009.00209.x
doi: 10.1111/j.1476-5381.2009.00209.x
Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ (2003) Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23(32):10331–10337. https://doi.org/10.1523/JNEUROSCI.23-32-10331.2003
doi: 10.1523/JNEUROSCI.23-32-10331.2003
Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2(4):395–402. https://doi.org/10.2174/1570159043359477
doi: 10.2174/1570159043359477
Ferrari A, Coccia CP, Bertolini A, Sternieri E (2004) Methadone–metabolism, pharmacokinetics and interactions. Pharmacol Res 50(6):551–559. https://doi.org/10.1016/j.phrs.2004.05.002 . PMID: 15501692
doi: 10.1016/j.phrs.2004.05.002
Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GEM (2009) Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 60(4):284–290. https://doi.org/10.1016/j.phrs.2009.04.002
doi: 10.1016/j.phrs.2009.04.002
Bulka A, Plesan A, Xu XJ, Wiesenfeld-Hallin Z (2002) Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 95(1–2):103–109. https://doi.org/10.1016/s0304-3959(01)00382-7
doi: 10.1016/s0304-3959(01)00382-7
Mattick RP, Breen C, Kimber J, Davoli M (2003) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev (2):CD002209. https://doi.org/10.1002/14651858.CD002209
Tan C, Wong JF, Yee CM, Hum A (2022) Methadone rotation for cancer pain: an observational study. BMJ Support Palliat Care 12(e6):e736–e739. https://doi.org/10.1136/bmjspcare-2019-002175
doi: 10.1136/bmjspcare-2019-002175
Ayonrinde OT, Bridge DT (2000) The rediscovery of methadone for cancer pain management. Med J Aust 173(10):536–540
doi: 10.5694/j.1326-5377.2000.tb139323.x
Freo U, Romualdi P, Kress HG (2019) Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res 12:1537–1551. https://doi.org/10.2147/JPR.S190162
doi: 10.2147/JPR.S190162
Raffa RB, Elling C, Tzschentke TM (2018) Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load.’ Adv Ther 35(10):1471–1484. https://doi.org/10.1007/s12325-018-0778-x
doi: 10.1007/s12325-018-0778-x
Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P (2017) From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci 21(7):1672–1683
Kress HG, Coluzzi F (2019) Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res 12:1553–1560. https://doi.org/10.2147/JPR.S191543
doi: 10.2147/JPR.S191543
Billeci D, Coluzzi F (2017) Tapentadol extended release for the management of chronic neck pain. J Pain Res 10:495–505. https://doi.org/10.2147/JPR.S129056
doi: 10.2147/JPR.S129056
Kögel B, De Vry J, Tzschentke TM, Christoph T (2011) The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. Neurosci Lett 491(2):104–107. https://doi.org/10.1016/j.neulet.2011.01.014
doi: 10.1016/j.neulet.2011.01.014
Torres-Sanchez S, Alba-Delgado C, Llorca-Torralba M, Mico JA, Berrocoso E (2013) Effect of tapentadol on neurons in the locus coeruleus. Neuropharmacology 72:250–258. https://doi.org/10.1016/j.neuropharm.2013.04.053
doi: 10.1016/j.neuropharm.2013.04.053
Butler SF, McNaughton EC, Black RA (2015) Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 16(1):119–130. https://doi.org/10.1111/pme.12524
doi: 10.1111/pme.12524
Pergolizzi J, Magnusson P, Coluzzi F, Breve F, LeQuang JAK, Varrassi G. Multimechanistic single-entity combinations for chronic pain control: a narrative review. Cureus. 14(6):e26000. https://doi.org/10.7759/cureus.26000
Pathan H, Williams J (2012) Basic opioid pharmacology: an update. Br J Pain 6(1):11–16. https://doi.org/10.1177/2049463712438493
doi: 10.1177/2049463712438493
Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM (2000) Cytochrome P450 2D6 and treatment of codeine dependence. J Clin Psychopharmacol 20(1):43
doi: 10.1097/00004714-200002000-00008
Chung KF (2008) Currently available cough suppressants for chronic cough. Lung 186(Suppl 1):S82-87. https://doi.org/10.1007/s00408-007-9030-1
doi: 10.1007/s00408-007-9030-1
Coluzzi F, Scerpa MS, Rocco M, Fornasari D (2022) The impact of P-glycoprotein on opioid analgesics: what’s the real meaning in pain management and palliative care? Int J Mol Sci 23(22):14125. https://doi.org/10.3390/ijms232214125
doi: 10.3390/ijms232214125
Minami K, Uezono Y, Ueta Y (2007) Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci 103(3):253–260. https://doi.org/10.1254/jphs.cr0060032
doi: 10.1254/jphs.cr0060032
Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43(13):879–923. https://doi.org/10.2165/00003088-200443130-00004
doi: 10.2165/00003088-200443130-00004
Frost DA, Soric MM, Kaiser R, Neugebauer RE (2019) Efficacy of tramadol for pain management in patients receiving strong cytochrome P450 2D6 inhibitors. Pharmacotherapy 39(6):724–729. https://doi.org/10.1002/phar.2269
doi: 10.1002/phar.2269
Altarifi AA, Moerke MJ, Alsalem MI, Negus SS (2020) Preclinical assessment of tramadol abuse potential: effects of acute and repeated tramadol on intracranial self-stimulation in rats. J Psychopharmacol 25:269881120944153. https://doi.org/10.1177/0269881120944153
doi: 10.1177/0269881120944153
Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68(2):419–457. https://doi.org/10.1124/pr.114.009209
Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK (1996) Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 214(2–3):131–134. https://doi.org/10.1016/0304-3940(96)12917-7
doi: 10.1016/0304-3940(96)12917-7
Kiguchi N, Ko MC (2019) Effects of NOP-related ligands in nonhuman primates. Handb Exp Pharmacol 254:323–343. https://doi.org/10.1007/164_2019_211
doi: 10.1007/164_2019_211
Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, Schröder W, Kögel BY, Beier H, Englberger W, Schunk S, De Vry J, Jahnel U (2014) Frosch SCebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther 349(3):535–548. https://doi.org/10.1124/jpet.114.213694
doi: 10.1124/jpet.114.213694
Ziemichod W, Kotlinska J, Gibula-Tarlowska E, Karkoszka N, Kedzierska E (2022) Cebranopadol as a novel promising agent for the treatment of pain. Molecules 27(13):3987. https://doi.org/10.3390/molecules27133987
doi: 10.3390/molecules27133987
Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC (2016) A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci U S A. 13;113(37):E5511–8. https://doi.org/10.1073/pnas.1605295113 . Epub 2016 Aug 29
Wang Y, Qin D, Guo Z, Shi F, Cannella N, Ciccocioppo R, Li H (2022) Research progress on the potential novel analgesic BU08028. Eur J Pharmacol 914:174678. https://doi.org/10.1016/j.ejphar.2021.174678
doi: 10.1016/j.ejphar.2021.174678
Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC (2018) A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 10(456):eaar3483. https://doi.org/10.1126/scitranslmed.aar3483
Varga BR, Streicher JM, Majumdar S (2023) Strategies towards safer opioid analgesics-a review of old and upcoming targets. Br J Pharmacol 180(7):975–993. https://doi.org/10.1111/bph.15760
doi: 10.1111/bph.15760
Wang YH, Chai JR, Xu XJ, Ye RF, Zan GY, Liu GY, Long JD, Ma Y, Huang X, Xiao ZC, Dong H, Wang YJ (2018) Pharmacological characterization of dezocine, a potent analgesic acting as a κ partial agonist and μ partial agonist. Sci Rep 8(1):14087. https://doi.org/10.1038/s41598-018-32568-y
doi: 10.1038/s41598-018-32568-y
Khroyan TV, Cippitelli A, Toll N, Lawson JA, Crossman W, Polgar WE, Toll L (2017) In vitro and in vivo profile of PPL-101 and PPL-103: mixed opioid partial agonist analgesics with low abuse potential. Front Psychiatry 8:52. https://doi.org/10.3389/fpsyt.2017.00052
doi: 10.3389/fpsyt.2017.00052
Uprety R, Che T, Zaidi SA, Grinnell SG, Varga BR, Faouzi A, Slocum ST, Allaoa A, Varadi A, Nelson M, Bernhard SM, Kulko E, Le Rouzic V, Eans SO, Simons CA, Hunkele A, Subrath J, Pan YX, Javitch JA, McLaughlin JP, Roth BL, Pasternak GW, Katritch V, Majumdar S (2021) Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. Elife 10:e56519. https://doi.org/10.7554/eLife.56519
doi: 10.7554/eLife.56519
Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-Bocanegra L, Tanna RS, McIntosh S, Raja HA, Graf TN, Hemby SE, Paine MF, Oberlies NH, Cech NB (2020) Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions. Sci Rep 10(1):19158. https://doi.org/10.1038/s41598-020-76119-w
doi: 10.1038/s41598-020-76119-w
Vekariya RH, Lei W, Ray A, Saini SK, Zhang S, Molnar G, Barlow D, Karlage KL, Bilsky EJ, Houseknecht KL, Largent-Milnes TM, Streicher JM, Ananthan S (2020) Synthesis and structure-activity relationships of 5’-aryl-14-alkoxypyridomorphinans: identification of a μ opioid receptor agonist/δ opioid receptor antagonist ligand with systemic antinociceptive activity and diminished opioid side effects. J Med Chem 63(14):7663–7694. https://doi.org/10.1021/acs.jmedchem.0c00503
doi: 10.1021/acs.jmedchem.0c00503
Shen KF, Crain SM (1995) Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture. Brain Res 701(1–2):158–166. https://doi.org/10.1016/0006-8993(95)00999-1
doi: 10.1016/0006-8993(95)00999-1
Lei W, Vekariya RH, Ananthan S, Streicher JM (2020) A novel Mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. J Pain 21(1–2):146–160. https://doi.org/10.1016/j.jpain.2019.05.017
doi: 10.1016/j.jpain.2019.05.017
Bu H, Liu X, Tian X, Yang H, Gao F (2015) Enhancement of morphine analgesia and prevention of morphine tolerance by downregulation of β-arrestin 2 with antigene RNAs in mice. Int J Neurosci 125(1):56–65. https://doi.org/10.3109/00207454.2014.896913
doi: 10.3109/00207454.2014.896913
Yang CH, Huang HW, Chen KH, Chen YS, Sheen-Chen SM, Lin CR (2011) Antinociceptive potentiation and attenuation of tolerance by intrathecal β-arrestin 2 small interfering RNA in rats. Br J Anaesth 107(5):774–781. https://doi.org/10.1093/bja/aer291
doi: 10.1093/bja/aer291
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286(5449):2495–2498. https://doi.org/10.1126/science.286.5449.2495
doi: 10.1126/science.286.5449.2495
Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408(6813):720–723. https://doi.org/10.1038/35047086
doi: 10.1038/35047086
Raehal KM, Walker JKL, Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314(3):1195–1201. https://doi.org/10.1124/jpet.105.087254
doi: 10.1124/jpet.105.087254
Markham A (2020) Oliceridine: first approval. Drugs 80(16):1739–1744. https://doi.org/10.1007/s40265-020-01414-9
doi: 10.1007/s40265-020-01414-9
Daksla N, Wang A, Jin Z, Gupta A, Bergese SD (2023) Oliceridine for the management of moderate to severe acute postoperative pain: a narrative review. Drug Des Devel Ther 17:875–886. https://doi.org/10.2147/DDDT.S372612
doi: 10.2147/DDDT.S372612
Eleswarpu SS, Habib AS (2021) Oliceridine in the treatment of moderate to severe acute pain. Pain Manag 11(3):237–248. https://doi.org/10.2217/pmt-2020-0087
doi: 10.2217/pmt-2020-0087
Fossler MJ, Sadler BM, Farrell C, Burt DA, Pitsiu M, Skobieranda F, Soergel DG (2018) Oliceridine (TRV130), a novel G protein-biased ligand at the μ-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. I: Development of a pharmacokinetic/pharmacodynamic model. J Clin Pharmacol 58(6):750–761. https://doi.org/10.1002/jcph.1076
DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344(3):708–717. https://doi.org/10.1124/jpet.112.201616
doi: 10.1124/jpet.112.201616
Liang DY, Li WW, Nwaneshiudu C, Irvine KA, Clark JD (2019) Pharmacological characters of oliceridine, a μ-opioid receptor G-protein-biased ligand in mice. Anesth Analg 129(5):1414–1421. https://doi.org/10.1213/ANE.0000000000003662
doi: 10.1213/ANE.0000000000003662
Mori T, Takemura Y, Arima T, Iwase Y, Narita M, Miyano K, Hamada Y, Suda Y, Matsuzawa A, Sugita K, Matsumura S, Sasaki S, Yamauchi T, Higashiyama K, Uezono Y, Yamazaki M, Kuzumaki N, Narita M (2021) Further investigation of the rapid-onset and short-duration action of the G protein-biased μ-ligand oliceridine. Biochem Biophys Res Commun 534:988–994. https://doi.org/10.1016/j.bbrc.2020.10.053
doi: 10.1016/j.bbrc.2020.10.053
Singla N, Minkowitz HS, Soergel DG, Burt DA, Subach RA, Salamea MY, Fossler MJ, Skobieranda F (2017) A randomized, phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res 6(10):2413–2424. https://doi.org/10.2147/JPR.S137952
doi: 10.2147/JPR.S137952
Singla NK, Skobieranda F, Soergel DG, Salamea M, Burt DA, Demitrack MA, Viscusi ER (2019) APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract 19(7):715–731. https://doi.org/10.1111/papr.12801
doi: 10.1111/papr.12801
Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N (2019) APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res 12:927–943. https://doi.org/10.2147/JPR.S171013
doi: 10.2147/JPR.S171013
Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155(9):1829–1835. https://doi.org/10.1016/j.pain.2014.06.011
doi: 10.1016/j.pain.2014.06.011
Ayad S, Demitrack MA, Burt DA, Michalsky C, Wase L, Fossler MJ, Khanna AK (2020) Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin Drug Investig 40(8):755–764. https://doi.org/10.1007/s40261-020-00936-0
doi: 10.1007/s40261-020-00936-0
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Da Duan, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537(7619):185–190. https://doi.org/10.1038/nature19112
Yudin Y, Rohacs T (2019) The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels. Br J Pharmacol 176(17):3110–3125. https://doi.org/10.1111/bph.14702
doi: 10.1111/bph.14702
Kudla L, Bugno R, Skupio U, Wiktorowska L, Solecki W, Wojtas A, Golembiowska K, Zádor F, Benyhe S, Buda S, Makuch W, Przewlocka B, Bojarski AJ, Przewlocki R (2019) Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine. Br J Pharmacol 176(23):4434–4445. https://doi.org/10.1111/bph.14805
doi: 10.1111/bph.14805
Ding H, Kiguchi N, Perrey DA, Nguyen T, Czoty PW, Hsu FC, Zhang Y, Ko MC (2020) Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. Br J Anaesth 125(4):596–604. https://doi.org/10.1016/j.bja.2020.06.057
doi: 10.1016/j.bja.2020.06.057
Hill R, Disney A, Conibear A, Sutcliffe K, Dewey W, Husbands S, Bailey C, Kelly E, Henderson G (2018) The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol 175(13):2653–2661. https://doi.org/10.1111/bph.14224
doi: 10.1111/bph.14224
Podlewska S, Bugno R, Kudla L, Bojarski AJ, Przewlocki R (2020) Molecular modeling of µ opioid receptor ligands with various functional properties: PZM21, SR-17018, morphine, and fentanyl-simulated interaction patterns confronted with experimental data. Molecules 25(20):4636. https://doi.org/10.3390/molecules25204636
doi: 10.3390/molecules25204636
Kudla L, Bugno R, Podlewska S, Szumiec L, Wiktorowska L, Bojarski AJ, Przewlocki R (2021) Comparison of an addictive potential of μ-opioid receptor agonists with G protein bias: behavioral and molecular modeling studies. Pharmaceutics 14(1):55. https://doi.org/10.3390/pharmaceutics14010055
doi: 10.3390/pharmaceutics14010055
Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aubé J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9(456):ra117. https://doi.org/10.1126/scisignal.aai8441
Bedini A, Di Cesare ML, Micheli L, Baiula M, Vaca G, De Marco R, Gentilucci L, Ghelardini C, Spampinato S (2020) Functional selectivity and antinociceptive effects of a novel KOPr agonist. Front Pharmacol 11:188. https://doi.org/10.3389/fphar.2020.00188
doi: 10.3389/fphar.2020.00188
Khan MIH, Sawyer BJ, Akins NS, Le HV (2022) A systematic review on the kappa opioid receptor and its ligands: new directions for the treatment of pain, anxiety, depression, and drug abuse. Eur J Med Chem 243:114785. https://doi.org/10.1016/j.ejmech.2022.114785
doi: 10.1016/j.ejmech.2022.114785
Santino F, Gentilucci L (2023) Design of κ-opioid receptor agonists for the development of potential treatments of pain with reduced side effects. Molecules 28(1):346. https://doi.org/10.3390/molecules28010346
doi: 10.3390/molecules28010346
Kutlu Yalcin E, Araujo-Duran J, Turan A (2021) Emerging drugs for the treatment of postsurgical pain. Expert Opin Emerg Drugs 26(4):371–384. https://doi.org/10.1080/14728214.2021.2009799
doi: 10.1080/14728214.2021.2009799
Fugal J, Serpa SM (2023) Difelikefalin: a new κ-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease-associated pruritus. Ann Pharmacother 57(4):480–488. https://doi.org/10.1177/10600280221115889
doi: 10.1177/10600280221115889